CD5 and diffuse large B-cell lymphoma: Accumulating data have revealed that CD5-positive (CD5+) DLBCL patients fail to benefit from rituximab-based immunochemotherapy and intensive regimens, with the 5-year survival rate as only 40% (3–5).